Condition: Type2diabetes · Heart Failure With Reduced Ejection Fraction · Sponsor: The University of Texas Health Science Center at San Antonio
The study team will examine the effects of elevated plasma ketone levels following initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM) individuals with heart failure (HF) with reduced ejection fraction (HFrEF) providing an energy-rich fuel that is taken up with great avidity by the myocardium, to measure change in Left Ventricle diastolic and systolic function
This description comes directly from the study's public registry record.
Ralph DeFronzo, MD · 210-567-6691 · defronzo@uthscsa.edu
Sivaram Neppala, MD · 210-358-7200 · neppalas@uthscsa.edu
Always discuss trial participation with your own doctor first.
| Texas Diabetes Institute - University Health System | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06229678